Sutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Truist Financial

Key Points

• Truist Financial upgraded Sutro Biopharma to a "strong‑buy", joining several analysts who recently raised ratings and price targets; MarketBeat shows a consensus rating of Moderate Buy with a consensus target price of $40.78.
• Sutro shares opened near $37.32 (50‑day MA $26.11, 200‑day MA $16.72), with a market cap of about $618M, a 12‑month range of $6.74–$39.74, and roughly 96.99% institutional ownership.
• Despite upgrades, analyst forecasts (notably Lifesci) still show multi‑year negative EPS through 2030, underscoring development‑stage risk, ongoing cash burn and potential future dilution.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) was upgraded by equities researchers at Truist Financial to a "strong-buy" rating in a research note issued to investors on Monday,Zacks.com reports.

Several other equities analysts also recently weighed in on the stock. Wells Fargo & Company raised shares of Sutro Biopharma from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $8.00 to $27.00 in a report on Tuesday, March 24th. Citizens Jmp raised their price objective on shares of Sutro Biopharma from $35.00 to $41.00 and gave the company a "market outperform" rating in a research report on Thursday, April 23rd. Lifesci Capital upgraded shares of Sutro Biopharma to a "strong-buy" rating in a research note on Friday, May 1st. HC Wainwright raised shares of Sutro Biopharma from a "neutral" rating to a "buy" rating and upped their target price for the stock from $10.00 to $28.00 in a report on Tuesday, March 24th. Finally, Leerink Partners initiated coverage on shares of Sutro Biopharma in a report on Tuesday, April 7th. They issued an "outperform" rating and a $38.00 target price for the company. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Sutro Biopharma presently has a consensus rating of "Moderate Buy" and a consensus target price of $40.78.

Sutro Biopharma Stock Down 2.8%

STRO stock opened at $37.32 on Monday. The business's 50-day moving average price is $26.11 and its 200-day moving average price is $16.72. The stock has a market cap of $618.39 million, a P/E ratio of -1.43 and a beta of 1.63. Sutro Biopharma has a twelve month low of $6.74 and a twelve month high of $39.74.

Institutional Trading of Sutro Biopharma

A number of large investors have recently added to or reduced their stakes in STRO. State of Tennessee Department of Treasury purchased a new stake in shares of Sutro Biopharma during the 4th quarter worth approximately $86,000. Sigma Planning Corp purchased a new position in shares of Sutro Biopharma in the first quarter valued at $312,000. Jane Street Group LLC bought a new stake in Sutro Biopharma in the fourth quarter worth $265,000. Bridgeway Capital Management LLC raised its stake in Sutro Biopharma by 232.6% during the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company's stock valued at $37,000 after purchasing an additional 30,000 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in Sutro Biopharma by 51.3% during the third quarter. Bank of America Corp DE now owns 119,434 shares of the company's stock valued at $104,000 after purchasing an additional 40,488 shares in the last quarter. Institutional investors own 96.99% of the company's stock.

Key Headlines Impacting Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Lifesci Capital reiterated a "Strong‑Buy" on STRO and provided multi‑year forecasts that imply improvement versus the current consensus — Lifesci projects FY2026 loss of ($6.60) and FY2027 loss of ($5.45), which are meaningfully narrower than the consensus full‑year loss of ($9.17). This analyst optimism can support upside if clinical or program milestones validate the thesis. MarketBeat: STRO analyst note
• Neutral Sentiment: The report lays out specific quarterly EPS forecasts (e.g., Q1 2026 ($2.78), Q2 2026 ($1.52), Q3/Q4 2026 ($1.34) each, and Q1–Q4 2027 around ($1.39)–($1.44)), giving investors a framework to model cash needs and runway but not announcing new company data or milestones. Use these figures to update your own financial models. MarketBeat: STRO analyst detail
• Negative Sentiment: Despite the upbeat rating, Lifesci's forecasts still show multi‑year negative EPS (FY2026–2030 remain losses, e.g., FY2030 ($6.31)), underscoring ongoing development-stage risk, potential future dilution, and continued cash burn — factors that can pressure the stock if program readouts or financing developments disappoint. MarketBeat: STRO risk context

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.